RSC Publishing


Publishing

 

Cover image for Highlights in Chemical Biology , select for current issue

Highlights in Chemical Biology

Chemical biology news and research from across RSC Publishing.



Two-pronged approach to RNA binding


04 September 2009

The prospect of using RNA as a drug target is of great interest to scientists, but due to its complex structure, designing ligands that bind to it is challenging. Scientists from the University of North Carolina at Chapel Hill, US, have overcome these difficulties by combining two weak ligands to make an RNA-binding conjugate that is far better than the sum of its parts.

A schematic in which a beta-hairpin peptide and an RNA intercalator are combined to form a conjugate

Combining two RNA-binding ligands gives a conjugate that binds both single and double stranded regions of RNA

"Our system is the first example of coupling a sequence-selective threading intercalator with a beta-hairpin peptide that is known to selectively bind unpaired bases"
'Although cooperative binding has been explored in the past,' says Marcey Waters, who carried out the research with Lauren Cline, 'our system is the first example of coupling a sequence-selective threading intercalator with a -hairpin peptide that is known to selectively bind unpaired bases.' The result is a system that simultaneously targets both the single- and double-stranded regions of RNA. While the intercalator threads between two G-C base pairs adjacent to bulges in the RNA, the peptide targets exposed bases in the RNA's single-stranded loops and bulges, resulting in binding that is at least 30 times more favourable than for either unit alone. 

Yitzhak Tor, who investigates RNA-small molecule interactions at the University of California, San Diego, US, says that Waters' results are an important step forward. 'Increasing the affinity and selectivity of designer ligands to RNA is challenging and this work elegantly demonstrates the advantage of combining two distinct recognition modes.' He suggests that similar combined ligand systems could ultimately be useful if they are applied to RNA sequences that are validated as therapeutic targets.

"This work elegantly demonstrates the advantage of combining two distinct recognition modes"
- Yitzhak Tor
Waters agrees that targeting medicinally relevant RNA structures is an important future goal in this area. 'The ability to develop high affinity, high selectivity ligands would open up RNA as a feasible drug target for the treatment of many types of disease, such as HIV,' she says.

Bailey Fallon

Enjoy this story? Spread the word using the 'tools' menu on the left or add a comment to the Chemistry World blog. 

Link to journal article

Design of a -hairpin peptide-intercalator conjugate for simultaneous recognition of single stranded and double stranded regions of RNA
Lauren L. Cline and Marcey L. Waters, Org. Biomol. Chem., 2009, 7, 4622
DOI: 10.1039/b913024a

Also of interest

RNA targeting through binding of small molecules: Studies on t-RNA binding by the cytotoxic protoberberine alkaloid coralyne
Md. Maidul Islam, Prateek Pandya, Surat Kumar and Gopinatha Suresh Kumar, Mol. BioSyst., 2009, 5, 244
DOI: 10.1039/b816480k

Screening of a branched peptide library with HIV-1 TAR RNA
David I. Bryson, Wenyu Zhang, W. Keith Ray and Webster L. Santos, Mol. BioSyst., 2009, 5, 1070
DOI: 10.1039/b904304g

Protein-Nucleic Acid Interactions

Protein-Nucleic Acid Interactions

Copyright: 2008
Phoebe A Rice

Written by a team of experts, this book bridges the gap between the DNA- and RNA- views of protein-nucleic acid recognition which are often treated as separate fields.


Nucleic Acids in Chemistry and Biology

Nucleic Acids in Chemistry and Biology

Copyright: 2006
G Michael Blackburn

This book is ideal for graduate and undergraduates students of chemistry and biochemistry, as well as new researchers to the field.


Sequence-specific DNA Binding Agents

Sequence-specific DNA Binding Agents

Copyright: 2006
Michael J Waring

This book discusses diverse modes of binding of antibiotics and drugs to DNA, emphasising matters that are important or promising for cancer treatment.